How an Orthopedic Practice Can Add a Peptide Therapy Program

A peptide therapy program for orthopedic practices can be structured as a clinician-governed adjunctive service, but it should not be treated as a product-access business. The practice must separate orthopedic care from program eligibility decisions, verify applicable state and federal requirements, review sourcing and consent, and substantiate every health-related advertising claim.

What should an orthopedic practice decide first?

The first decision is whether the proposed service has a clearly defined clinical purpose, responsible clinician, and governance model. An orthopedic practice should not begin with a product list or marketing campaign. It should define how the program relates—or does not relate—to orthopedic diagnosis, surgery, rehabilitation, and follow-up.

A useful starting distinction is:

• Orthopedic care: Diagnosis, treatment planning, procedures, rehabilitation coordination, and follow-up performed by appropriately licensed clinicians.
• Adjunctive or wellness program: A separately governed service with its own eligibility criteria, informed-consent process, documentation, follow-up, and escalation pathways.
• Technology and administration: Intake, scheduling, telehealth workflow, communications, records support, and pharmacy coordination that do not control clinical decisions.

The program should not imply that an intervention repairs tissue, prevents surgery, accelerates healing, reduces recovery time, or works for athletes unless the exact claim is supported by appropriate evidence and reviewed before publication. FTC guidance says objective health claims need a reasonable basis before dissemination, and testimonials or endorsements do not replace substantiation.

For broader planning context, review the telehealth programs hub and the specialty practice telehealth launch timeline before selecting a launch model.

How does a separation-of-roles model work?

The separation-of-roles model assigns clinical judgment, operations, sourcing review, and marketing accountability to distinct functions. A platform or administrative vendor can support workflow, but it should not decide who qualifies, pressure clinicians to prescribe, or make efficacy claims on the practice’s behalf.

This structure helps an established specialty practice use existing clinical and administrative capabilities without turning the orthopedic brand into a promise about a particular intervention. MDLaunchr, the brand behind WhiteLabelClinic.com, is designed to help qualified businesses evaluate and coordinate technology, operational, compliance, clinical-network, and fulfillment relationships. Clinical eligibility and prescribing remain with independently licensed clinicians.

What should the practice review about products and sourcing?

The practice should review each proposed product and route independently; the general term “peptide” does not establish legality, quality, safety, or clinical appropriateness. FDA states that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality, and compounded products should not be described as FDA-approved, FDA-reviewed, generic equivalents, or clinically equivalent to an approved drug.

The regulatory pathway also matters. FDA describes section 503A as applying to compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, subject to statutory conditions. Section 503B applies to registered outsourcing facilities that compound sterile drugs and comply with current good manufacturing practice requirements. Registration does not mean FDA approves or licenses the facility’s products.

The practice’s diligence file should address:

• The applicable compounding pathway for the proposed product.
• Current facility registration or licensing information, where relevant.
• Inspection, quality, product-documentation, recall, and adverse-event processes.
• Whether the applicable bulk-substance and compounding conditions are satisfied.
• Who independently verifies the source rather than relying only on promotional material.
• How product-quality complaints are escalated and documented.

The distinction between these pathways is explained in more detail in 503A versus 503B pharmacy considerations. The practice should obtain qualified pharmacy and legal review before adding a product or source to its operating model.

What eligibility, consent, and follow-up questions belong in the workflow?

Eligibility and safety questions should be documented by the responsible clinician, not generated solely by a software vendor or marketing funnel. The workflow should prompt review of the patient’s clinical situation, relevant history, possible exclusions, alternatives, and the need for referral.

Use this governance checklist before launch:

• What clinical problem is the program intended to address?
• Is the service adjunctive, investigational, wellness-oriented, or part of ordinary medical care?
• Which conditions, medications, allergies, pregnancy status, prior reactions, or other factors require exclusion or referral?
• Who conducts the medical evaluation and retains clinical responsibility?
• What evidence supports the proposed use for the relevant population and outcome?
• Does consent explain that a compounded product is not FDA-approved and may not have undergone FDA premarket review?
• What alternatives are discussed?
• How are adverse events, product-quality complaints, recalls, and urgent symptoms escalated?
• When is the patient referred back to the orthopedic team, primary-care clinician, emergency care, or another specialist?
• How are records, communications, and vendor access documented?

The consent process should be specific to the service under review. A generic telehealth acknowledgment does not necessarily address the relevant risks, limitations, alternatives, product status, or follow-up expectations.

How do telehealth and privacy requirements affect an orthopedic clinic peptide therapy program?

A telehealth workflow must account for the patient’s physical location and the clinician’s authority to practice there. HHS explains that cross-state requirements vary and may involve a full license, temporary-practice authority, reciprocity, a compact pathway, or telehealth registration. The practice should verify patient location at each encounter, confirm the clinician’s authority in that location, obtain consent, and document the process.

National availability should not be assumed. Before serving a resident of any state, the practice should review that state’s medical and pharmacy requirements, telehealth registration rules, scope-of-practice standards, corporate-practice-of-medicine considerations, entity structure, informed-consent rules, advertising restrictions, fee-splitting concerns, record-retention duties, and cash-pay disclosures. The relevant state medical board, pharmacy board, and professional licensing authorities should be part of that review.

Privacy roles also need to be mapped. HHS says a covered entity engaging a business associate must have a written business associate agreement describing the services and privacy and security obligations. The practice should determine whether the platform, scheduling vendor, documentation tool, laboratory interface, marketing technology, or care-coordination service is a business associate, another type of service provider, or a separate entity. A vendor’s statement that it is “HIPAA-compliant” does not by itself complete the practice’s analysis.

For a more detailed operational view, compare the step-by-step telehealth patient intake workflow with the program’s clinical and escalation requirements.

How should the practice advertise the program?

Advertising should describe the service accurately without converting clinical uncertainty into a performance promise. FDA’s June 17, 2026 notice addressed telehealth promotion of compounded drugs and warned against representations that a compounded product is FDA-approved, FDA-reviewed, a generic equivalent, or sourced from an “FDA-approved” or “FDA-licensed” pharmacy or outsourcing facility.

FTC guidance applies to websites, social media, seminars, promotional materials, and marketing conducted indirectly through practitioners or intermediaries. Before publishing a sports medicine program page, the practice should ask:

1. 1What exact service is being offered?
2. 2What population and outcome does each claim address?
3. 3What evidence supports that exact claim?
4. 4Does the wording imply prevention, healing, performance improvement, or superiority?
5. 5Does a testimonial communicate an implied result that the practice cannot substantiate?
6. 6Are product status and limitations described accurately?

Avoid unsupported language such as “accelerates healing,” “repairs tissue,” “prevents surgery,” “shortens recovery,” or “works for athletes.” A qualified reviewer should examine the final copy, landing pages, social posts, referral materials, and any clinician endorsements.

Can an orthopedic practice bill insurance or Medicare for the program?

Reimbursement should not be assumed. CMS maintains a calendar-year list of services payable under the Medicare Physician Fee Schedule when furnished through telehealth, and its 2026 materials include changes affecting telehealth and therapy services. The practice must determine whether the service is medically necessary, separately billable, bundled, cash-pay, or excluded from a payer arrangement.

Before launch, obtain billing and compliance review for coding, payer contracts, patient disclosures, refunds, documentation, and financial arrangements. A cash-pay structure still requires accurate advertising and clear communication about what the fee covers.

Why might an established orthopedic practice launch faster than a new brand?

An established practice may already have licensed clinicians, patient-facing policies, scheduling staff, record systems, referral relationships, and a trusted specialty context. Those assets can reduce operational setup compared with a new brand. They do not eliminate clinical, regulatory, privacy, sourcing, advertising, or billing review.

A disciplined sequence is:

1. 1Define the program’s clinical purpose and boundaries.
2. 2Assign independent clinical responsibility and escalation ownership.
3. 3Review state licensure, entity, pharmacy, and telehealth requirements.
4. 4Evaluate proposed products and sources through qualified reviewers.
5. 5Build intake, consent, documentation, follow-up, and adverse-event workflows.
6. 6Map privacy roles and execute required agreements.
7. 7Review claims and marketing evidence before publication.
8. 8Test the workflow with staff before accepting patients.
9. 9Reassess the model as federal or state guidance changes.

MDLaunchr and WhiteLabelClinic.com can support the intake, telehealth, pharmacy-coordination, and compliance infrastructure review around that sequence. The platform does not replace the independently licensed clinician, the practice’s counsel, or the applicable regulators. To move from concept to diligence, review your provider, pharmacy, and intake workflow before publishing a program offer.